NCT03787303: Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma

NCT03787303
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 105 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have documented history of hypothyroidism
Exclusions: 
https://ClinicalTrials.gov/show/NCT03787303

Comments are closed.

Up ↑